Article
Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma.
Pediatric blood & cancer - 1 Oct 2014
Rihani Ali, Van Maerken Tom, De Wilde Bram, Zeka Fjoralba, Laureys Geneviève, Norga Koen, Tonini Gian Paolo, Coco Simona, Versteeg Rogier, Noguera Rosa, Schulte Johannes H, Eggert Angelika, Stallings Raymond L, Speleman Frank, Vandesompele Jo
Abstract excerpt
While a polymorphism located within the promoter region of the MDM2 proto-oncogene, SNP309 (T > G), has previously been associated with increased risk and aggressiveness of neuroblastoma and other tumor entities, a protective effect has also been reported in certain other cancers. In this study, we evaluated the association of MDM2 SNP309 with outcome in 496 patients with neuroblastoma and its effect on MDM2...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.